Introduction {#Sec1}
============

Ascending aorta dilatation is sometimes concomitantly associated with aortic valve disease. It is generally recommended to surgically intervene on the ascending aorta once the maximum diameter is above 4.5 cm in the setting of other surgical cardiac procedures \[[@CR1]\]. This is to avoid the possible risk of future aorta dilatation or the possibility of aortic dissection and rupture \[[@CR2]\]. The dilated ascending aorta can be surgically addressed by radical ascending aorta replacement with a tube graft or by the less popular and more conservative reduction aortoplasty, with or without external wrapping \[[@CR3]\]. The following sections describes a modified reduction aortoplasty with concomitant cardiac procedures in high risk patients.

Patients {#Sec2}
========

A series of 9 patients are described after local ethical board approval with individual consent for every patient in the series. They had a dilated ascending aortas (4.5 cm to \< 5.0 cm) in the setting of concomitant aortic valve replacement with left ventricular dysfunction from July 2016 to December 2018 at our institution. Some patients required additional mitral repair and/or coronary bypass grafting (CABG). All patients successfully underwent "spiral" aortoplasty to reduce the aortic diameter. The ascending aorta was measured for each patient on follow-up at the level of the mid ascending aorta with the use of CT angiography (Table [1](#Tab1){ref-type="table"}).Table 1Case series of 9 patients who underwent "spiral" aortoplasty with concomitant aortic valve replacement +/− CABG +/− mitral valve repairSeries no.Age / SexAAD before surgeryLV EFDiagnosisBicuspid aortic valveEuro ScoreProcedureFollow-up timeCondition on follow-up153 M4.7 cm30%CHF+54.50%Aortoplasty30 monthsStable. AAD 3.8 cmSevere AIAVR (mosaic \#27)Moderate MRMV repair (annuloplasty \#30)Atrial fibrillationMAZEStrokeLAA clot extraction and ligationClot in the LAA270 M4.5 cm25%CHF+20.40%Aortoplasty28 monthsStable. AAD 3.6 cmSevere AIAVR (mosaic \#27)360 M4.5 cm35%Severe AS17.70%Aortoplasty25 monthsStable. AAD 3.7 cmCAD: LAD stenosisAVR (mosaic \#25)CABG: LIMA-LAD467 M4.6 cm30%Severe AS20.20%Aortoplasty21 monthsStable. AAD 3.8 cmModerate MRAVR (mosaic \#21)CAD: LAD stenosisMV repair (annuloplasty \#28)CABG: LIMA-LAD562 F4.5 cm40%Severe AS+9.50%Aortoplasty17 monthsStable. AAD 3.3 cmMild MRAVR (mosaic \#23)CAD: ostial RCA stenosisCABG: SVG-RCA655 M4.8 cm15%Severe AI+24.00%Aortoplasty16 monthsStable. AAD 3.9 cmCAD: 3 vessel diseaseAVR (mosaic \#27)CABG: LIMA-LAD, SVG-OM, SVG-PDA750 M4.8 cm20%CHF+84.70%Aortoplasty14 monthsAAD 3.7 cm. The patient presented with aortic prosthesis endocarditis and aortic root abscess 10 months after the first operation. He underwent redo surgery with aortic annulus reconstruction and AVR. The patient was discharged on chronic dialysis and died 4 months later due to refractory heart failure.Severe AIAVR (mosaic \#27)Severe MRMV repair (annuloplasty \#30)Chronic kidney disease (creatinine 200 μmol/L)866 M4.6 cm40%Severe AI12.80%Aortoplasty6 monthsStable. AAD 3.5 cmCAD: RCA total occlusionAVR (mosaic \#25)CABG: SVG-PDA972 M4.5 cm40%Severe AS+11.00%AortoplastyCAD: 3 vessel diseaseAVR (mosaic \#23)4 monthsStable. AAD 3.5 cmCABG: LIMA-LAD, SVG-OM, SVG-PDA*AA* ascending aorta, *AAD* ascending aorta diameter, *AI* aortic regurgitation, *AS* aortic stenosis, *AVR* aortic valve replacement, *CABG* coronary artery bypass grafting, *CAD* coronary artery disease, *CHF* congestive heart failure, *LAA* left atrial appendage, *LAD* left anterior descending, *LIMA* left internal mammary, *LV EF* left ventricular ejection fraction, *MR* mitral regurgitation, *OM* obtuse marginal, RCA: right coronary artery, *PDA* posterior descending artery, *SVG* saphenous vein graft

Technique {#Sec3}
=========

The heart was accessed through a median sternotomy and cardiopulmonary bypass was initiated via central cannulation. The arterial cannula was inserted in the proximal aortic arch. Prior to applying the cross clamp, an umbilical tape was looped around the backside of the ascending aorta and was lifted before applying the cross clamp to ensure the clamp captured the entire aortic wall. The clamp was positioned as high as possible in the ascending aorta. An oblique aortotomy was performed in the middle of the anterior segment of the ascending aorta and was spirally extended downward and laterally toward the non-coronary sinus, stopping at the aortic annulus, and superiorly toward the left shoulder up to the bifurcation of the pulmonary artery. The aortic valve was replaced though this access. Concomitant procedures such as distal coronary grafts and/or mitral repair were performed prior to the aortic procedure. The aortotomy closure was sandwiched between 2 strips of Teflon felt and sutured together using a double closure technique. The Suture incorporated 0.5 cm of aortic tissue on either side during closure in order to reduce the aortic size by 1 cm. (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1**a** The expansion of the aorta occurs on a multiplanar axis. **b** "Spiral" aortoplasty allows for the circumferential wall tension reduction along multiple planes. **c** The aortotomy is performed in a spiral fashion extending from the pulmonary bifurcation and down to the annulus of the non-coronary sinus. **d** The aortotomy is sandwiched between two strips of Teflon felt incorporating 0.5 cm of tissue on either side. **e** The proximal coronary grafts are implanted either above or below the suture line

Comments {#Sec4}
========

Fusiform ascending aorta aneurysm is commonly observed in patients with aortic valve disease, particularly in those with a bicuspid aortic valve. The dilatation is likely due to intrinsic factors harbored within the connective tissue of the aortic wall. The multiplanar dilatation causes elongation and circumferential expansion of the aorta. Previously described reduction aortoplasty techniques primarily reduce the aortic diameter and wall tension at a single plane in the mid-anterior wall of the ascending aorta \[[@CR4]\]. The technique described in this series has the same advantages of other described aortoplasty approaches in high-risk patients with the added advantage of reducing the wall tension and size along the circumferential and longitudinal planes. External wrapping was avoided because of the reported risks of "under-the-wrap" aortic atrophy and rupture, wrap migration, and the need to construct proximal coronary anastomosis in the ascending aorta. Bicuspid aortic valve was present in over half of the series. All patients showed an approximately 1-cm reduction of the mid-ascending aortic diameter on echocardiographic and tomographic follow-up. This technique should not be used in patients with dilated aortic root, ascending aortas with a diameter of \> 5.0 cm, in patients with acute aortic dissection, or in patients with syndromic connective tissue disorders such as Marfan's syndrome. The series is limited by its small size, short follow-up, and the potential risk for re-dilatation of the ascending aorta.

In summary, this series describes a limited number of high risk patients who successfully underwent concomitant aortic valve replacement with reduction aortoplasty and other added procedures. The spiral aortoplasty technique has the advantage of multiplanar aortic size reduction without the need to perform the more radical ascending aorta replacement in moderately dilated ascending aorta.

AA

:   Ascending aorta

AAD

:   Ascending aorta diameter

AI

:   Aortic regurgitation

AS

:   Aortic stenosis

AVR

:   Aortic valve replacement

CABG

:   Coronary artery bypass grafting

CAD

:   Coronary artery disease

CHF

:   Congestive heart failure

LAA

:   Left atrial appendage

LAD

:   Left anterior descending

LIMA

:   Left internal mammary

LV EF

:   Left ventricular ejection fraction

MR

:   Mitral regurgitation

OM

:   Obtuse marginal

PDA

:   Posterior descending artery

RCA

:   Right coronary artery

SVG

:   Saphenous vein graft

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This project was supported by College of Medicine Research Centre, Deanship of Scientific Research, King Saud University.

RIN MD, conceived, performed and wrote the manuscript. The author read and approved the final manuscript.

None.

Data related to the manuscript are available upon request.

The series was approved via The Institutional Review Board for the King Saud University College of Medicine (E-19-3849).

Consent was obtained for publication from each patient in the series.

The author declares that he has no competing interests.
